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Vaccination of pigs with a DNA construct expressing an
influenza virus M2–nucleoprotein fusion protein exacerbates
disease after challenge with influenza A virus
Paul P. Heinen, Frans A. Rijsewijk, Els A. de Boer-Luijtze and Andre! T. J. Bianchi
Division of Mammalian Virology, Institute for Animal Science and Health (ID-Lelystad), PO Box 65, 8200 AB Lelystad, The Netherlands
In mice, vaccines inducing antibodies to the extracellular domain of the M2 protein (M2e) can
confer protection to influenza A virus infection. Unlike the surface glycoproteins, haemagglutinin
and neuraminidase, this domain of M2 is highly conserved and is therefore a potential broad-
spectrum immunogen. In this study, the protection conferred by vaccines inducing antibodies to
M2e was evaluated in a challenge model for swine influenza in pigs. A protein resulting from the
fusion between M2e and the hepatitis B virus core protein (M2eHBc), with or without adjuvant, was
evaluated. In addition, a DNA construct expressing a fusion protein between M2e and influenza
virus nucleoprotein (M2eNP) was evaluated to see if the broad-spectrum protection conferred by
antibodies could be further enhanced by T helper cells and cytotoxic T cells. All vaccines induced
an antibody response against M2e, and the M2eNP DNA vaccine additionally induced an influenza
virus-specific lymphoproliferation response. However, after challenge with a swine influenza virus
(H1N1), no protection was observed in the vaccinated groups compared with the non-vaccinated
control group. On the contrary, vaccinated pigs showed more severe clinical signs than the control
pigs. The M2eNP DNA-vaccinated pigs showed the most severe clinical signs and three out of six
pigs died on days 1 and 2 post-challenge. These results indicate that antibodies to M2e, especially
in combination with cell-mediated immune responses, exacerbate disease. Thus, clinical signs after
infection should be observed closely in further studies using M2e as an immunogen and caution
should be exercised in using M2e in humans.
Introduction
Influenza A virus expresses two highly immunogenic, but
variable, transmembrane proteins : haemagglutinin (HA) and
neuraminidase (NA). In humans, new epidemic strains arise
every 1–2 years as a result of selected point mutations in these
two surface glycoproteins, a phenomenon known as antigenic
drift. Sometimes, an exchange of the HA and}or NA gene
segment with an animal influenza virus occurs, a phenomenon
known as antigenic shift, and this may result in a flu pandemic.
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Current human influenza vaccines are updated yearly to induce
immune responses specific for the prevalent strains. These
vaccines are efficacious when the HA of the vaccine strain
matches that of the circulating virus, but not when it differs as
a result of antigenic drift or shift.
Another transmembrane protein is the M2 protein. This
protein is relatively invariant from strain to strain, and a
number of studies have shown that it is a potential broad-
spectrum immunogen. Vaccination with the M2 protein in the
absence of other influenza virus proteins reduced virus
infection (Frace et al., 1999 ; Slepushkin et al., 1995), and
therapeutic treatment with a mAb specific for the extracellular
domain of M2 (M2e) was shown to reduce pulmonary virus
titres by 100- to 1000-fold in mice (Mozdzanowska et al.,
1999 ; Treanor et al., 1990). In a previous study in pigs, we
observed that the antibody response to M2e, which was low
after a primary influenza virus H3N2 infection, was clearly
boosted by a subsequent infection with H1N1, indicating that
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antibodies to M2e may have a role in heterosubtypic immunity
(Heinen et al., 2001). In contrast to the HA protein, the M2
protein is not accessible to antibody and therefore antibodies
to M2e are not virus-neutralizing. However, they can bind to
the M2e on infected host cells and reduce virus replication by
interfering with virus budding (Zebedee & Lamb, 1989) and by
mediating the killing of infected lung epithelial cells by
complement or by cells of the innate immune system (antibody-
dependent cytotoxicity) (Mozdzanowska et al., 1999). In
addition, antibodies that bind before budding of the virions
could hinder them from infecting cells or could enhance the
uptake by phagocytic cells via the Fc receptor.
Because the M2 protein itself seems to be a weak
immunogen and only antibodies to the extracellular domain of
the protein can be expected to protect, Neirynck et al. (1999)
combined this highly conserved domain with the hepatitis B
virus core protein (Neirynck et al., 1999). The resulting fusion
protein (M2eHBc) facilitated the presentation of M2e and
induced partial immunity in mice. In the present study, we
investigated the protection conferred by this fusion protein,
with or without adjuvant, in a challenge model for swine
influenza in pigs. In addition, we evaluated whether the broad-
spectrum protection conferred by antibodies could be further
enhanced by inducing T helper and cytotoxic T lymphocytes
(CTLs). T helper cells can mediate recovery from influenza
virus infection by the promotion of an antiviral antibody
response (Mozdzanowska et al., 1997 ; Topham & Doherty,
1998) and CTL response (Riberdy et al., 2000). CTLs have been
proposed to be the major mediator of heterosubtypic immunity
and many studies have indeed shown that CTLs contribute to
protection in mice (Epstein et al., 2000 ; Mozdzanowska
et al., 2000 ; Topham & Doherty, 1998 ; Ulmer et al., 1998).
Moreover, a previous study we performed indicated that CTLs
also have a role in heterosubtypic immunity in pigs (Heinen et
al., 2001). After infection, a large proportion of these CTLs
recognize conserved epitopes of the nucleoprotein (NP). In
mice, more than 15% of CTLs in the lungs after primary and
more than 65% after secondary heterosubtypic influenza





peptide (Doherty & Christensen, 2000, Flynn et al.,
1998, 1999). Therefore, we made a DNA construct expressing
a fusion protein betweenM2e and influenza virusNP (M2eNP).
It was expected that the expression of M2eNP by DNA
vaccination would induce an antibody response to the
conserved M2e, as well as a T helper and CTL response to the
conserved NP, and would confer a better protection than the
M2eHBc fusion protein.
Methods
+ Propagation of influenza virus. The influenza virus strains
A}Sw}Best}96 (H1N1) and A}Sw}Oedenrode}96 (H3N2) were iso-
lated from pneumonic lung tissue of pigs from outbreaks of influenza
during a recent field survey (Loeffen et al., 1999). Except for the HA and




Fig. 1. (A) Alignment of the amino acid sequences of the extracellular
domain of the M2 protein (M2e) from European swine and human
influenza viruses. (B) Schematic representation of the expression vector
M2eNP–VR1012. The expression vector was constructed from pVR1012,
a mammalian expression vector containing the HCMV immediate-early
transcriptional enhancer, promoter and intron A regulatory elements and
the poly(A) signal and transcription termination sequences of the bovine
growth hormone in a pUC18 backbone. The gene fragments encoding
M2e and the NP of influenza virus A/Sw/Oedenrode/96 were fused and
cloned into the multiple cloning site of the vector. (C) Analysis of the
M2eNP fusion protein. Influenza virus-infected minipig kidney cells and
M2eNP–VR1012-transfected or non-transfected SK-6 cells were incubated
with 35S-labelled cysteine and methionine. Proteins from the cell lysates
were immunoprecipitated with an influenza virus NP-specific mAb and
analysed by SDS–PAGE. The M2eNP fusion protein is larger than the wild-
type NP (59 and 56 kDa, respectively).
genetic reassortment between the two subtypes occurred in pigs, in
which the H3N2 virus acquired all other proteins from the H1N1 virus
(Castrucci et al., 1993). The viruses were isolated in primary cultures of
porcine thyroid cells, then passaged three times in these cells and then
passaged twice in Madin–Darby canine kidney (MDCK) cells (ECACC
No. 84 121 903). Virus stocks were produced and stored at fi70 °C until
used as inoculum or as antigen in haemagglutination inhibition (HI)
assays, ELISAs and T cell proliferation assays.
+ M2e–hepatitis B virus core fusion protein (M2eHBc). Purified
M2eHBc (Neirynck et al., 1999) was kindly provided by Sabine Neirynck
(Flanders Interuniversity Institute for Biotechnology). The amino acid
sequence of the M2e is derived from a human influenza virus strain and
is present in almost all presently known human influenza A virus field
strains. This sequence differs from the M2e of European swine influenza
viruses in six out of the 23 amino acids that form the M2e (Fig. 1a).
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+ Construction, preparation and analysis of the M2eNP DNA
construct. The two regions of gene segment 7 encoding the complete
M2 protein were amplified by RT–PCR from RNA of influenza virus
strains A}Sw}Oedenrode}96 (H3N2) and A}Sw}Best}96 (H1N1).
Primers used were Uni 12 (5« AGCAAAAGCAGG 3«) and V7 166R (5«
TAGCCACTCCATGAGAGCC 3«), and V7 675 (5« ATGAGAACAGT-
TGGGACTC 3«) and V7 1007R (5« TTACTCCAGCTCTATGTTGAC
3«). The region of gene segment 5 encoding the complete NP of influenza
virus A}Sw}Oedenrode}96 (H3N2) was amplified using the primers
Uni12 and V5 1546R (5« GAAACAAGGGTATTTTTCT 3«). The NP
was cloned into Escherichia coli using a pGEM-T cloning kit (Promega).
The nucleotide sequences of M2 and NP were determined using the
PRISM Ready Dye T Deoxy Terminator cycle sequencing kit and the
ABI PRISM 310 Genetic Analyser (Perkin-Elmer). These sequences were
sent toGenBank and the accession numbers are AF385294 and AF385295
for the nucleotide and amino acid sequence of the M2 protein of
A}Sw}Best}96 (H1N1), respectively, and AF385296 and AF385297 for
the M2 protein and AF385293 for the NP of A}Sw}Oedenrode}96
(H3N2).
The first 24 N-terminal amino acid residues (MSLLTEVETPTRNGW-
ECRYSDSND) that form M2e were identical for the swine influenza
H1N1 and H3N2 virus strains and differed in six residues from the
universal human sequence (Fig. 1A). A 102 residue oligonucleotide was
synthesized, which comprised the complete sequence encoding swine
M2e downstream of a Kozak motif for initiation of translation in
vertebrates (Kozak, 1987). A 106 residue antisense strand was also
synthesized and the two oligonucleotides were annealed together by
heating for 2 min at 95 °C and subsequent cooling, thus resulting in a
102 bp fragment with a sticky end. For directional cloning, a BclI
restriction site was added at the 5« end of the fragment. The sticky 3« end
could be directly ligated on to the DNA fragment encoding the NP after
restriction of this fragment with SmlI. The fragment resulting from this
fusion was cloned into the XbaI and BclI cloning sites of the eukaryotic
expression vector pVR1012 (Vical), downstream of the human cytomega-
lovirus (HCMV) promoter (Fig. 1B). The pVR1012 plasmid lacking the
M2eNP DNA insert served as a control. Plasmids were propagated in the
HB101 strain of E. coli and purified using Qiagen columns.
Transient expression of the M2eNP fusion protein was confirmed in
confluent monolayers of SK-6 cells (Kasza et al., 1972), using mAbs
against the NP (ATCC No. HB 65, H16-L10-4R5) and M2e (14C2-S1-4),
kindly provided by Walter Gerhard (The Wistar Institute). The correct
size of the fusion protein was confirmed by radio-immunoprecipitation
(RIP), using the mAb against the NP and subsequent SDS–PAGE
(Fig. 1C).
+ Pigs, immunization and challenge. Twenty-four Dutch Land-
race pigs were obtained from the SPF herd of the Institute for Animal
Science and Health. They were assigned to four groups of six pigs and
each group was housed in a separate room. Starting at the age of 10
weeks, all pigs were inoculated three times at 3 week intervals with 2 ml
inoculum. Pigs in the M2eHBc group were immunized intramuscularly
with 50 lg protein in saline. Pigs in the M2eHBc plus adjuvant group
were immunized intramuscularly with 50 lg protein in adjuvant
(CoVaccine). Pigs in the M2eNP DNA group were injected intradermally,
behind the ear, with 200 lg of M2eNP-encoding plasmid. Pigs in the
control group were injected with 200 lg of empty plasmid.
At post-inoculation day (PID) 70, 4 weeks after the third vaccination,
all pigs were challenged with the field isolate A}Sw}Best}96 (H1N1).
Pigs were challenged with an aerosol produced by nebulization of 2 ml
culture supernatant containing 10) TCID
&!
virus, using an air brush
device (Badger, No. 100LG, Franklin, IL, USA). The institute«s ethics
committee for experiments in animals approved the experiment.
+ Clinical observations and sampling. Clinical signs and body
temperature of all pigs were monitored and oropharyngeal fluid was
collected daily for 8 days following challenge inoculation (PID 70–78).
The following clinical signs were scored : laboured breathing, abdominal
breathing, anorexia, apathy and coughing. Blood was collected at PID 0,
3, 7, 10, 17, 24, 31, 38, 45, 52, 66, 73, 77, 80 and 87. Serum was collected
to determine the titres of HI antibodies in the HI assay and of IgG
antibodies specific for M2e and NP in ELISAs. Heparinized blood was
collected for the isolation of peripheral blood mononuclear cells (PBMCs)
to be used in a T cell proliferation assay. Bronchioalveolar lavage fluid
(BALF) and nasal swabs (NS) were collected at PID 66, 72, 74, 78 and 88.
To collect NS and BALF, animals were anaesthetized by injection
(ketamine, midazolam, medetomidine). NS was collected to determine
antibody titres in the anti-NP IgA ELISA, and BALF was used to monitor
the changes in phenotypes of BALF cells by flow cytometry.
+ Virus isolation. Ten-fold serial dilutions, starting at a dilution of
1 :10, of oropharyngeal fluid were prepared in cell culture infection
medium (McCoy«s medium without serum, supplemented with 5 lg}ml
trypsin). Dilutions were inoculated on MDCK cells in microtitre plates,
which were incubated at 37 °C and examined for a cytopathic effect after
4 days. Of the samples that were negative in the microtitre assay, 1 ml
was tested for the presence of virus by inoculating a monolayer of
MDCK cells in 25 ml tissue culture flasks. Virus titres were calculated by
the Spearman–Ka$ rber method.
+ Haemagglutination inhibition (HI) assay. The HI assay was
performed essentially as described previously (Kendal et al., 1982), using
0–5% chicken erythrocytes for haemagglutination and four haemagglu-
tinating units of A}Sw}Best}96 (H1N1).
+ ELISA for IgG specific for M2e and for IgG and IgA specific
for NP. The ELISA to detect IgG specific for M2e was recently described
(Heinen et al., 2001). A synthetic peptide with the amino acid sequence
MSLLTEVETPTRNGWECRY of the M2e of the swine influenza viruses
was made and a conjugate of this peptide with keyhole limpet
haemocyanin was used to coat 96-well ELISA plates (Costar EIA}RIA,
cat. no. 3590, Costar, Cambridge, UK). Plates were then blocked with 1%
BSA in PBS, incubated with twofold serial dilutions of serum samples
starting at a dilution of 1 :20, incubated with a mAb against swine IgG1
(23.49.1) conjugated to HRP and then incubated at room temperature
with chromogen}substrate solution. The absorbance at 450 nm was read
with an ELISA reader (Spectra Reader, SLT Labinstruments) and antibody
titres were expressed as the reciprocal of the sample dilution still giving
an optical density (OD) value of 1–0.
The ELISAs to measure influenza virus NP-specific IgG and IgA
antibodies in pigs were as described previously (Heinen et al., 2001).
Absorbance and antibody titres were determined as described for the
anti-M2e IgG ELISA.
+ Flow cytometric analysis of BALF cells. The technique that was
used to obtain BALF has been previously described (van Leengoed &
Kamp, 1989). Approximately 30 ml of PBS was added to the BALF to
give a total volume of 50 ml. The BALF cells were collected by
centrifugation at 300 g for 10 min at 4 °C and washed once with 50 ml
PBS. Cells were then suspended in 1 ml PBS containing 2% heat-
inactivated bovine serum and 0–01% sodium azide (FACS buffer) and the
total number of recovered cells was determined. Cells were spun down in
96-well U-bottomed microtitre plates by centrifugation at 230 g for
3 min. The supernatant was discarded and the cells were incubated for
30 min on ice with various combinations of mAbs to leukocyte
differentiation antigens. The mAbs used to differentiate myeloid cells
BIFD
P. P. Heinen and others
were directed against the following cell markers : SWC3 (clone 74-22-15,
IgG1) and CD163 (clone CVI 517.2, IgG2b). The mAbs used to
differentiate lymphoid cells were directed against : CD4 (clone 74-12-4,
IgG2b), CD5 (clone b53b7, IgG1), CD6 (clone a38b2, IgG1) and CD8
(clone 295}33, IgG2a). These mAbs have been previously used to
analyse changes in the phenotype of leukocytes in the BALF of pigs
infected with influenza virus (Heinen et al., 2001). After incubation, the
cells were washed three times with FACS buffer and then incubated for
30 min on ice with the appropriate fluorescein isothiocyanate (FITC)- or
phycoerythrin (PE)-conjugated goat anti-mouse IgG isotype-specific
antibodies, diluted in FACS buffer. Subsequently, the cells were washed
three times, resuspended in FACS buffer and transferred to tubes.
Fluorescence was measured using a FACScan flow cytometer (Becton
Dickinson).
+ T cell proliferation assay. The T cell proliferation assay to
measure influenza virus-specific T cell responses of pigs was performed
essentially as described for pseudorabies virus (Kimman et al., 1995).
Briefly, PBMCs were isolated from heparinized blood samples by
centrifugation on to Lymphoprep (Nycomed Pharma A) and were
washed twice with PBS. The isolated PBMCs were seeded in 96-well flat-
bottomed plates (M29, Greiner) at a density of 5‹10& cells per well in
100 ll medium (RPMI 1640 containing 10% porcine serum, 2 mM l-
glutamine, 50 lM b-mercaptoethanol, 200 U}ml penicillin, 200 lg}ml
streptomycin and 100 U}ml mycostatin). To the PBMCs, 100 ll medium
containing 10& TCID
&!
influenza virus A}Sw}Best}96 (H1N1), 2 lg}ml
purified M2eHBc fusion protein, a control sample prepared from non-
infected cells (mock control) or 5 lg}ml Con A (vitality control) were
added in quadruplicate. After incubation for 4 days at 37 °C in a 5% CO
#
atmosphere, the cultures were pulsed with 0–4 lCi [$H]thymidine
(Amersham). After incubation for 4 h, cells were harvested and the
incorporated radioactivity was measured in a Betaplate scintillation
counter (Wallac, EG&G Instruments). Proliferation was expressed as the
number of counts (mean of quadruplicate) of antigen-stimulated PBMCs
minus the number of counts of the mock-control-stimulated PBMCs
(delta counts).
+ Statistics. Comparisons of mean clinical score, temperatures, virus
excretion and changes in the phenotype of cells in the BALF between
immunized groups and control groups and comparison of T cell
proliferation when PBMCs were stimulated with ConA before and after
challenge were evaluated by two-sided Student’s t-tests. Probability (P)
values ! 0–05 were considered significant.
Results
Clinical signs and virus excretion
Unexpectedly, clinical signs after challenge were more
severe in all immunized groups compared with the control
group. In the M2eNP DNA group, clinical signs were
extremely severe and one pig died on post-challenge day
(PCD) 1 and two more died on PCD 2, during the lung lavage.
The clinical signs of laboured breathing, abdominal breathing,
anorexia, apathy and coughing were all given a score of 0 if
absent and 1 if present. The mean accumulated clinical scores
of all groups are presented in Fig. 2(A). The highest clinical
score was found in the M2eNP DNA group, in which three
pigs died.
In all groups, pigs developed fever (& 40 °C) for at least 1
day between PCD 0 and 6. The mean temperatures in the




Fig. 2. Mean clinical score (A), temperatures (B) and virus excretion (C)
of pigs immunized with M2eHBc fusion protein (_), M2eHBc fusion
protein›adjuvant (U), M2eNP DNA (D) and of control pigs (*), after
challenge infection. Pigs were immunized three times at 3 week intervals
and challenged 4 weeks after the third immunization with influenza virus
A/Sw/Best/96 (H1N1). In the M2eNP DNA-immunized group, three pigs
died on PCD 1 and 2. Results are presented as the mean‡SD (nfl6).
The means in each immunized group were compared with the mean in the
control group. Significant differences (P!0–05) of the mean in the
M2eHBc fusion protein (a), M2eHBc fusion protein›adjuvant (b) and
M2eNP DNA (c) immunized groups are indicated.
the contrary, pigs in the control group showed the highest
mean temperatures, whereas in the M2eNP DNA group, mean
temperatures were the lowest (Fig. 2B).
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Fig. 3. Mean serum IgG antibody response to M2e and the influenza virus
NP of pigs immunized with M2eHBc fusion protein (_), M2eHBc fusion
protein›adjuvant (U), M2eNP DNA (D) or control DNA (*). Pigs were
immunized (arrows) three times at 3 week intervals and challenged 4
weeks after the third immunization with influenza virus A/Sw/Best/96
(H1N1). In the M2eNP DNA-immunized group, three pigs died on PCD 1
and 2. Results are presented as the mean‡SD (nfl6).
No significant reduction in virus excretion was observed in
the immunized groups compared with the control group (Fig.
2C). In all groups, pigs excreted virus from PCD 1–5.
M2e-specific serum IgG, NP-specific serum IgG and
nasal IgA and HI antibody responses
In all immunized groups, an antibody response against M2e
was detected by ELISA after vaccination. The response was
highest in the M2eHBc protein plus adjuvant group, in-
termediate in the M2eNP DNA group and low in the M2eHBc




Fig. 4. Mean lymphocyte proliferation responses of PBMCs of pigs when
stimulated with influenza virus A/Sw/Best/96 (H1N1), M2eHBc protein or
ConA. Pigs were immunized with M2eHBc fusion protein (_), M2eHBc
fusion protein›adjuvant (U), M2eNP DNA (D) or control DNA (*). Pigs
were immunized (arrows) three times at 3 week intervals and challenged
4 weeks after the third immunization with influenza virus A/Sw/Best/96
(H1N1). In the M2eNP DNA-immunized group, three pigs died on PCD 1
and 2. Results are presented as the mean‡SD (nfl6).
After challenge, an increase in the antibody titre to M2e
was observed, which was fastest in the M2eNP DNA group,
probably as a result of the promotion of the antibody response
by T helper cells in this group.
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Fig. 5. Changes in the lymphocyte population in the lungs after challenge of pigs immunized with M2eHBc fusion protein (_),
M2eHBc fusion protein›adjuvant (U), M2eNP DNA (D) or control DNA (*). Pigs were immunized three times at 3 week
intervals and challenged 4 weeks after the third immunization with influenza virus A/Sw/Best/96 (H1N1). In the M2eNP DNA-
immunized group, three pigs died on PCD 1 and 2. Results are presented as the mean‡SD (nfl6). The means in each
immunized group were compared with the mean in the control group. Significant differences (P!0–05) of the mean in the
M2eHBc fusion protein (a), M2eHBc fusion protein›adjuvant (b) and M2eNP DNA (c) immunized groups are indicated.
Also, an antibody response against NP was detected in the
M2eNP DNA group. The titre against the NP did not correlate
with the titre against M2e. In pigs with high titres against the
NP, low titres against M2e were found and vice versa,
showing an individual preference for epitopes. Nevertheless,
all pigs were able to respond to the peptide because all pigs
showed a detectable antibody response to M2e in the
M2eHBc›adjuvant group, and in a previous study, all pigs
sequentially infected with influenza H1N1 and H3N2 virus
showed a detectable response (Heinen et al., 2001).
After challenge, the titre against NP in the M2eNP DNA
group quickly increased to a maximum between day 4 and 7
after challenge, which was faster than in the other groups (Fig.
3B). No nasal IgA response against the NP was detected before
challenge. After challenge, all groups responded with an anti-
NP IgA response, which, like the serum IgG response, was
fastest in the M2eNP DNA group (results not shown).
No significant differences between groups were observed
in the HI response after challenge (results not shown).
T cell proliferation
Before challenge, a proliferation response of PBMCs was
observed only in the M2eNP DNA group when cells were
stimulated with influenza virus A}Sw}Best}96 (Fig. 4A).
When cells were stimulated with M2eHBc protein a response
was observed only in the M2eHBc plus adjuvant group (Fig.
4B). The absence of a proliferation response of PBMCs from
M2eNP DNA-vaccinated pigs when stimulated with M2eHBc,
and of M2eHBc-vaccinated pigs when stimulated with in-
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fluenza virus, indicates that T cells are only stimulated by the
carrier protein and not by the M2e peptide.
After challenge, the antigen-specific proliferation response
decreased strongly, especially in the M2eNP DNA group (Fig.
4A). All groups developed a similar proliferation response to
stimulation with influenza A}Sw}Best}96 after challenge with
this virus.
The lymphoproliferation response of PBMCs when stimu-
lated with ConA dropped significantly after challenge in all
immunized groups (P! 0–001 for M2eHBc and M2eHBc›
adjuvant, P! 0–01 for M2eNP group), but not in the control
group (P" 0–05) (Fig. 4C).
Flow cytometric analysis of BALF cells
With the mAbs used, we distinguished two phenotypes of
myeloid cells : SWC3+CD163− cells (neutrophil phenotype)
and SWC3+CD163+ cells (monocyte and macrophage




CD4−CD5lowCD6−CD8−/low (TCR-cd+ phenotype) and a
heterogeneous population of CD5−CD8− cells (fi/fi T
cells). Because the cell numbers collected from the BALF of
pigs varied too much between samples, we could not calculate
the absolute numbers of cells of each phenotype.
The most relevant observation was a higher percentage of
T helper cells after challenge in the M2eNP DNA group than
in the other groups (Fig. 5). This percentage was significantly
(P! 0–05) higher than in the control group on PCD 4 and 8.
In addition, the percentage of CTLs was higher on PCD 4 in
the M2eNP DNA-vaccinated group than in the other groups.
Although this difference was not significant, it was observed
even though the percentage of T helper cells was also higher
in this group.
In the M2eHBc protein group and the M2eHBc protein
plus adjuvant group, the percentage of NK cells on PCD 4 was
higher than in the control group, but this difference was not
significant. No significant differences in the absolute number of
cells collected from the BALF or in the phenotype distribution
of the myeloid leukocyte populations after challenge were
observed between the groups (results not shown).
Discussion
The experimental vaccines evaluated in the present study
induced the desired immune responses. All vaccines induced an
antibody response to the extracellular domain of the M2
protein of influenza A virus and the M2eNP DNA vaccine
additionally induced an NP-specific lymphoproliferation re-
sponse. However, no protection was observed when the
vaccinated pigs were challenged with a swine influenza virus.
Clinical signs and virus excretion were not reduced in the
vaccinated groups compared with the non-vaccinated control
group. On the contrary, the vaccinated pigs showed more
severe clinical signs after challenge than the control pigs. In
particular, the M2eNP DNA-vaccinated pigs showed severe
signs and three out of six pigs died on days 1 and 2 post-
challenge. Previous studies in mice have suggested that
enhancement of the antibody response to the M2 protein by
vaccination may provide broad-spectrum immunity to humans
(Mozdzanowska et al., 1999 ; Neirynck et al., 1999 ; Treanor et
al., 1990), and we have suggested the same for pigs (Heinen et
al., 2001). However, the results of the present study in pigs
indicate that antibodies to M2e can also exacerbate disease.
Therefore, clinical signs after infection should be observed
closely in further studies using M2 as an immunogen and
caution should be exercised in using M2 in humans.
Vaccination of pigs with M2eHBc fusion protein did not
confer protection against influenza virus challenge infection,
which does not agree with results of a previous study in which
mice were partially protected after immunization with the
same material (Neirynck et al., 1999). The difference in results
could be caused by several reasons. One reason could be that
in the previous study a human challenge virus was used with
the same amino acid sequence of the M2e used for immuniza-
tion, while in the present study a swine influenza challenge
virus was used in which the sequence of the M2e differed (Fig.
1A). Nevertheless, antibodies induced by the immunization
were shown to bind to the peptide with the amino acid
sequence of the swine influenza challenge virus in the ELISA. If
the sequence difference caused the absence of protection after
vaccination, then this would mean that the spectrum of
protection conferred by immunization with M2e does not
include viruses with the swine influenza virus M2e sequence. A
second reason could be that, in the present study, pigs instead
of mice were used, and that pigs were challenged by aerosol
instead of intranasal instillation and the dose of challenge
differed. Since the pig is a natural host of influenza virus, the
swine influenza model seems a better model than the mouse
model to study vaccination strategies not only for pigs, but
also for humans. The course of infection with influenza A virus
in pigs is similar to that in humans. In fact, the same strains can
infect both pigs and humans, and pigs have been implicated as
a mixing reservoir for the generation of new pandemic strains
(Scholtissek, 1995). In contrast, influenza virus challenge in
rodents typically leads to lethal pulmonary infection and
protection is scored by survival rather than progression of
infection.
From the results obtained in this study, it is uncertain which
immune mechanism underlies the observed exacerbation of
disease. However, pigs in which only antibodies against M2e
were induced showed a severity of clinical signs after challenge
infection that was intermediate between the severity seen in
the non-immunized control group and the M2eNP DNA-
immunized group in which both antibodies to M2e and
influenza virus-specific T cells were induced. These findings
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suggest that the antibodies to M2e are involved, while in the
M2eNP DNA group, T helper cells played a role in the
exacerbation, probably by stimulating inflammatory responses.
In previous studies with NP DNA vaccination in mice (Epstein
et al., 2000 ; Ulmer et al., 1998 ; Zebedee & Lamb, 1989), but
also in pigs (Macklin et al., 1998), no exacerbation of disease
was observed after challenge, indicating that induction of T cell
immunity alone does not result in exacerbation of disease. In
contrast with antibodies against the HA protein, the antibodies
against M2e are not virus-neutralizing (VN), i.e. do not
prevent the attachment of influenza virions to the surface of
lung epithelial cells (Zebedee & Lamb, 1989). Therefore, many
cells will become infected and will express the M2 protein on
the membrane surface. Binding of the antibodies to the M2 will
thus promote the death of infected cells via several cell-
targeting (CT) mechanisms : (i) the antibodies can promote
contact with phagocytes either by reduction in surface charge,
by adherence directly via the Fc or via complement factor C3
bound to the Fc ; (ii) the antibodies can promote contact with
and killing by NK cells (antibody-dependent cellular cytotoxi-
city) ; or (iii) the antibodies can activate the full complement
system, producing direct membrane damage. Initially, we
expected these immune mechanisms to operate in protection
against influenza infection. However, in the present study, they
may have become overwhelmed because the virus challenge
dose was too high to cope with in the absence of VN
antibodies and the immune mechanisms caused damage rather
than providing protection. Because the M2-specific antibodies
do not prevent initial infection, it is likely that they are most
effective in the early stage of challenge infection when only a
few cells are infected, and they may need to be present in the
respiratory tract in sufficient amounts prior to challenge.
Induction of antibodies that act via CT mechanisms as well as
CTLs may be more effective by mucosal than by parenteral
vaccination.
Possibly, enhancement of disease by heterosubtypic im-
mune mechanisms could also occur in natural infections with
influenza virus. Heterotypic non-neutralizing antibodies have
been suggested to mediate enhancement of dengue infections,
causing dengue haemorrhagic fever and dengue shock syn-
drome (Chen et al., 2001 ; Morens, 1994 ; Yang et al., 2001). Did
immunity to the previous pandemic strain perhaps underlie the
extraordinarily high mortality in healthy people between the
age of 20 and 30 during the 1918 ‘Spanish flu« pandemic?
Vaccination with the DNA construct expressing a fusion
protein of M2e joined to the N terminus of the NP induced a
detectable antibody response to M2e. This shows that the NP
does present the M2e peptide to B cells and indicates that the
peptide is exposed on the surface of the fusion protein. Indeed,
a mAb to the peptide (14C2 ; Zebedee & Lamb, 1989) was
shown to bind to the fusion protein in an ELISA (result not
shown). To our knowledge, this is the first study to report the
presentation of a peptide to the immune system by fusion to
influenza virus NP. In addition, the DNA vaccination with the
M2eNP construct induced a lymphoproliferation response
similar to that seen after infection. Elevated percentages of T
helper cells as well as CTLs in the lungs of pigs 4 days post-
challenge compared with non-immunized pigs indicate that the
DNA vaccination indeed induces cellular immune responses in
addition to an antibody response.
In conclusion, the present study does not exclude the
possibility that M2e can be used as an immunogen to broaden
the spectrum of protection conferred by current influenza
vaccines. However, it does indicate that antibodies to M2e can
exacerbate clinical signs of disease and that caution should
therefore be exercised. Ways of inducing broad-spectrum
immunity other than by vaccination with M2e and}or NP only
might be safer. For example, successive infection with an
attenuated H1N1 strain and an H3N2 strain will induce both
M2e and probably other subtype cross-reactive IgA and IgG
antibodies, as well as CTLs, in the lungs. Although such drastic
vaccination strategies are not applicable to pig farming, they
might be applied as a strategy of immunization in case of a
future human pandemic.
The authors would like to thank Erwin van Wijk and Hinri Kerstens
for their assistance in the construction, preparation and analysis of the
M2eNP DNA construct and Professor J. T. van Oirschot for his critical
review of the manuscript.
References
Castrucci, M. R., Donatelli, I., Sidoli, L., Barigazzi, G., Kawaoka, Y. &
Webster, R. G. (1993). Genetic reassortment between avian and human
influenza A viruses in Italian pigs. Virology 193, 503–506.
Chen, R. F., Yeh, W. T., Yang, M. Y. & Yang, K. D. (2001). A model of
the real-time correlation of viral titers with immune reactions in antibody-
dependent enhancement of dengue-2 infections. FEMS Immunology and
Medical Microbiology 30, 1–7.
Doherty, P. C. & Christensen, J. P. (2000). Accessing complexity : the
dynamics of virus-specific T cell responses. Annual Review of Immunology
18, 561–592.
Epstein, S. L., Stack, A., Misplon, J. A., Lo, C. Y., Mostowski, H.,
Bennink, J. & Subbarao, K. (2000). Vaccination with DNA encoding
internal proteins of influenza virus does not require CD8+ cytotoxic T
lymphocytes : either CD4+ or CD8+ T cells can promote survival and
recovery after challenge. International Immunology 12, 91–101.
Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L. &
Doherty, P. C. (1998). Virus-specific CD8› T cells in primary and
secondary influenza pneumonia. Immunity 8, 683–691.
Flynn, K. J., Riberdy, J. M., Christensen, J. P., Altman, J. D. & Doherty,
P. C. (1999). In vivo proliferation of naive and memory influenza-
specific CD8+ T cells. Proceedings of the National Academy of Sciences, USA
96, 8597–8602.
Frace, A. M., Klimov, A. I., Rowe, T., Black, R. A. & Katz, J. M. (1999).
Modified M2 proteins produce heterotypic immunity against influenza A
virus. Vaccine 17, 2237–2244.
Heinen, P. P., de Boer-Luijtze, E. A. & Bianchi, A. T. J. (2001).
Respiratory and systemic humoral and cellular immune response of pigs
to a heterosubtypic influenza A virus infection. Journal of General Virology
82, 2697–2707.
BIFI
Influenza virus M2-based vaccines in pigs
Kasza, L., Shadduck, J. A. & Christofinis, G. J. (1972). Establishment,
viral susceptibility and biological characteristics of a swine kidney cell
line SK-6. Research in Veterinary Science 13, 46–51.
Kendal, A. P., Pereira, M. S. & Skehel, J. J. (1982). Concepts and
Procedures for Laboratory-based Influenza Surveillance. Washington, DC:
Department of Health and Human Services, Centers for Disease Control.
Kimman, T. G., de Bruin, T. M., Voermans, J. J., Peeters, B. P. &
Bianchi, A. T. (1995). Development and antigen specificity of the
lymphoproliferation responses of pigs to pseudorabies virus : dichotomy
between secondary B- and T-cell responses. Immunology 86, 372–378.
Kozak, M. (1987). At least six nucleotides preceding the AUG initiator
codon enhance translation in mammalian cells. Journal of Molecular Biology
196, 947–950.
Loeffen, W. L., Kamp, E. M., Stockhofe-Zurwieden, N., van Nieuwstadt,
A. P., Bongers, J. H., Hunneman, W. A., Elbers, A. R., Baars, J., Nell, T.
& van Zijderveld, F. G. (1999). Survey of infectious agents involved in
acute respiratory disease in finishing pigs. Veterinary Record 145,
123–129.
Macklin, M. D., McCabe, D., McGregor, M. W., Neumann, V., Meyer, T.,
Callan, R., Hinshaw, V. S. & Swain, W. F. (1998). Immunization of pigs
with a particle-mediated DNA vaccine to influenza A virus protects
against challenge with homologous virus. Journal of Virology 72,
1491–1496.
Morens, D. M. (1994). Antibody-dependent enhancement of infection
and the pathogenesis of viral disease. Clinical Infectious Diseases 19,
500–512.
Mozdzanowska, K., Furchner, M., Maiese, K. & Gerhard, W. (1997).
CD4› T cells are ineffective in clearing a pulmonary infection with
influenza type A virus in the absence of B cells. Virology 239, 217–225.
Mozdzanowska, K., Maiese, K., Furchner, M. & Gerhard, W. (1999).
Treatment of influenza virus-infected SCID mice with nonneutralizing
antibodies specific for the transmembrane proteins matrix 2 and
neuraminidase reduces the pulmonary virus titer but fails to clear the
infection. Virology 254, 138–146.
Mozdzanowska, K., Maiese, K. & Gerhard, W. (2000). Th cell-deficient
mice control influenza virus infection more effectively than Th- and B
cell-deficient mice : evidence for a Th-independent contribution by B cells
to virus clearance. Journal of Immunology 164, 2635–2643.
Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W. M. &
Fiers, W. (1999). A universal influenza A vaccine based on the
extracellular domain of the M2 protein. Nature Medicine 5, 1157–1163.
Riberdy, J. M., Christensen, J. P., Branum, K. & Doherty, P. C. (2000).
Diminished primary and secondary influenza virus-specific CD8+ T-cell
responses in CD4-depleted Ig(fi}fi) mice. Journal of Virology 74,
9762–9765.
Scholtissek, C. (1995). Molecular evolution of influenza viruses. Virus
Genes 11, 209–215.
Slepushkin, V. A., Katz, J. M., Black, R. A., Gamble, W. C., Rota, P. A. &
Cox, N. J. (1995). Protection of mice against influenza A virus challenge
by vaccination with baculovirus-expressed M2 protein. Vaccine 13,
1399–1402.
Topham, D. J. & Doherty, P. C. (1998). Clearance of an influenza A virus
by CD4+ T cells is inefficient in the absence of B cells. Journal of Virology
72, 882–885.
Treanor, J. J., Tierney, E. L., Zebedee, S. L., Lamb, R. A. & Murphy,
B. R. (1990). Passively transferred monoclonal antibody to the M2 pro-
tein inhibits influenza A virus replication in mice. Journal of Virology 64,
1375–1377.
Ulmer, J. B., Fu, T. M., Deck, R. R., Friedman, A., Guan, L., DeWitt, C.,
Liu, X., Wang, S., Liu, M. A., Donnelly, J. J. & Caulfield, M. J. (1998).
Protective CD4› and CD8› T cells against influenza virus induced by
vaccination with nucleoprotein DNA. Journal of Virology 72, 5648–5653.
van Leengoed, L. A. & Kamp, E. M. (1989). A method for broncho-
alveolar lavage in live pigs. Veterinary Quarterly 11, 65–72.
Yang, K. D., Yeh, W. T., Yang, M. Y., Chen, R. F. & Shaio, M. F. (2001).
Antibody-dependent enhancement of heterotypic dengue infections
involved in suppression of IFNgamma production. Journal of Medical
Virology 63, 150–157.
Zebedee, S. L. & Lamb, R. A. (1989). Growth restriction of influenza A
virus by M2 protein antibody is genetically linked to the M1 protein.
Proceedings of the National Academy of Sciences, USA 86, 1061–1065.
Received 2 January 2002; Accepted 26 March 2002
BIFJ
